ICO
Closing Date:
Seeking Neuroprotective Agents for Retinal and Ocular Conditions
Johnson & Johnson are a global pharmaceutical company with a strong track record of successful academic collaborations. They are interested in identifying research focused on novel treatments for retinal and ocular conditions.
Approaches of Interest
Johnson & Johnson are looking for any novel compounds or targets which could be used for retinal neuroprotection. This includes prevention of photoreceptor/retinal ganglion cell (RGC) apoptosis or degeneration.
The photoreceptor/RGC degeneration can be linked to any condition, but Johnson & Johnson are particularly...
To see the full details and submit your response please register now
Benefits of registration:
- Receive updates on the latest industry calls
- Quickly and easily respond to calls via your dashboard
- Build your academic profile